ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data Life Science Investing
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates Life Science Investing
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer Life Science Investing
HOPE Therapeutics, an NRx Subsidiary Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD Life Science Investing
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference Life Science Investing
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® Commercialization Life Science Investing
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 Life Science Investing
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy Life Science Investing
Incyte Announces the European Commission Approval of Zynyz® for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal Life Science Investing
Canada and CSL Seqirus, a Global Leader in Influenza Vaccines, agree on new Pandemic Preparedness Contract Life Science Investing
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights Life Science Investing
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Life Science Investing